Pertussis Vaccine Global Market Report 2024

The global pertussis vaccine market has grown steadily in recent years. It will grow from $5.26 billion in 2023 to $5.5 billion in 2024 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to disease prevalence, immunization programs, pediatric vaccination, regulatory approvals.

The global pertussis vaccine market is expected to see steady growth in the next few years. It will grow to $6.33 billion in 2028 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to booster vaccination, maternal immunization, immunization for healthcare workers, global health initiatives. Major trends in the forecast period include personalized immunization schedules, combination vaccines, vaccine equity initiatives, digital health for immunization.

The upward trend in childbirth rates is expected to be a significant growth driver for the pertussis vaccine market. Childbirth is the natural process of bringing a child into the world, marking the end of pregnancy and the beginning of a new life. The pertussis vaccine primarily targets children to provide protection against whooping cough and other severe, potentially life-threatening illnesses. For example, in May 2022, the U.S.-based Center for Disease Control and Prevention (CDC) reported 3.66 million births in the United States in 2021, a slight increase from 3.61 million in 2020. Additionally, in 2021, Canada, as per Statistics Canada, recorded a 2% rise in births, with numbers increasing from 360,552 in 2020 to 367,684 in 2021. Hence, the growing prevalence of childbirth rates is a significant factor propelling the expansion of the pertussis vaccine market.

The continuous growth of the geriatric population is anticipated to drive the expansion of the pertussis vaccine market. The geriatric population encompasses individuals in their later stages of life, typically aged 65 and older. The expanding number of older adults is a key contributor to the pertussis vaccine market. As more people enjoy longer lifespans, there is a heightened demand for pertussis vaccines to protect older individuals from this serious disease. For instance, in October 2022, the Switzerland-based World Health Organization projected that the global population of individuals aged 60 years and above is set to double by 2050, reaching 2.1 billion. Simultaneously, the number of individuals aged 80 years or older is expected to triple from 2020 to 2050, totaling 426 million. Consequently, the growing geriatric population is fostering the growth of the pertussis vaccine market.

The restricted availability of pertussis vaccines acts as a constraining factor on the growth of the pertussis vaccines market during the projected period. The limited accessibility to pertussis vaccines has resulted in adverse effects on their distribution and effectiveness, including constrained vaccine accessibility, escalated costs, decreased demand, delayed or incomplete immunization, and global ramifications. For instance, in July 2023, UNICEF (United Nations International Children's Emergency Fund) reported that approximately 14.3 million children did not receive any doses of pertussis vaccines (diphtheria-tetanus-pertussis DTP3) in 2022. Hence, this limited availability is impeding the expansion of the pertussis vaccines market.

Major enterprises engaged in the pertussis vaccine market are actively advancing innovative vaccines and securing regulatory approvals to maintain their market position. For instance, in October 2022, GSK plc., a UK-based pharmaceutical and biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval of BOOSTRIX. BOOSTRIX is a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) vaccine. It is administered during pregnancy to prevent pertussis (whooping cough) in newborn infants and is administered as a single upper arm muscle injection. Boostrix is recognized for its safety and effectiveness in pregnant women and their infants, effectively preventing pertussis, including severe cases of the disease.

In May 2022, GSK plc., a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for a sum of $2.1 billion. This strategic acquisition is a step taken by GSK to broaden its vaccine portfolio, enhance its outreach to patients, bolster its vaccine research and development pipeline, gain access to a potentially groundbreaking technology, and expand its scientific presence in the Boston region. Affinivax Inc. is a U.S.-based biotechnology enterprise specialized in the development of pertussis vaccines.

Major players in the pertussis vaccine market are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, BioNTech SE, Moderna Inc., Sinovac Biotech Ltd., CSL Limited, Astellas Pharma US Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma America Inc., PT Kalbe Farma Tbk, CSL Seqirus, Walvax Biotechnology Co.Ltd., Biological E. Limited, Serum Institute of India, Bavarian Nordic AS, PT Bio Farma, Bharat Biotech International Limited, Takeda Pharmaceutical Company, Panacea Biotec Limited, Beijing Minhai Biotechnology Co. Ltd., Protein Sciences Corporation, Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Gennova Biopharmaceuticals Ltd., Chiron Corporation.

North America was the largest region in the pertussis vaccine market in 2023. The regions covered in pertussis vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pertussis vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main products related to the pertussis vaccine include the DTaP (diphtheria, tetanus, and acellular pertussis) vaccine and the Tdap (tetanus, diphtheria, and pertussis) vaccine. The DTaP vaccine, which is also known as the DTP vaccine, is a combination vaccine intended to safeguard against three serious bacterial infections such as diphtheria, tetanus, and pertussis (whooping cough). These vaccines are available in both whole-cell and acellular formulations and are administered to individuals of various age groups, including children, adults, and infants. They are typically administered by healthcare professionals at vaccination centers, hospitals, and clinics.

This report provides pertussis vaccine market statistics, including pertussis vaccine industry global market size, regional shares, competitors with a pertussis vaccine market share, detailed pertussis vaccine market segments, market trends and opportunities and any further data you may need to thrive in the pertussis vaccine industry. This pertussis vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pertussis vaccine market consists of sales of adacel, daptacel, infanrix, kinrix, pediarix, pentacel and quadracel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.